Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
- cell therapy
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 239908
MultiTAA technology selectively expands non-engineered T cells, enhancing them with the ability to kill tumor cells by targeting multiple tumor-associated antigens simultaneously to prevent immune escape and generate durable immunity. Patient/donor T cells are not genetically modified and therefore the cost of generating Licensee's therapies is significantly reduced.
IPSCIO Record ID: 248290
IPSCIO Record ID: 3283
shall have the right to grant sublicenses consistent with this Agreement.
Diagnosis and classification of multiple myeloma
United States Patent 7,308,364
Diagnosis of multiple myeloma on gene expression profiling
IPSCIO Record ID: 307594
The companies will partner to develop Licensorâ€™s next-generation bispecific antibody programs, epcoritamab (DuoBodyÂ®-CD3xCD20), DuoHexaBodyÂ®-CD37 and DuoBody-CD3x5T4. The collaboration combines Licensorâ€™s world-class discovery and development engine and next-generation bispecific antibody therapeutic candidates with Licenseeâ€™s deep clinical expertise, innovative antibody-drug conjugate (ADC) platform and global commercial leadership in hematological cancers. Licensorâ€™s DuoBody-CD3 technology engages and directs cytotoxic T cells selectively to tumors to elicit an immune response towards malignant tumor cells. Licenseeâ€™s ADC technology allows the delivery of a therapeutic toxin directly to cancer cells while sparing normal, healthy cells, providing for a more targeted, less toxic treatment approach.
Licensor is a biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Licensors technology base consists of validated and proprietary next generation antibody technologies – the DuoBodyÂ® platform for generation of bispecific antibodies, the HexaBodyÂ® platform, which creates effector function enhanced antibodies, the HexElectÂ® platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency and the DuoHexaBodyÂ® platform, which enhances the potential potency of bispecific antibodies through hexamerization.
Licensee has a clinical expertise, innovative antibody-drug conjugate (ADC) platform and global commercial leadership in hematological cancers.